Cubist Pharmaceuticals Ranks No. 1 in The Boston Globe's Annual Globe 100 List of Best Performing Companies
Lexington, Mass. -- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it was ranked first among the "Top 100" Massachusetts-based publicly traded companies by The Boston Globe in its 21st annual "Globe 100" listing released today. Cubist is only the third life sciences company in Massachusetts to appear at the top of the Globe 100 rankings, and as a company that researches, develops, and brings to market pharmaceutical products, the first of its kind to achieve this distinction.
Michael W. Bonney, Cubist's president and CEO, said: "Being #1 in the Globe 100 list of the best-performing public companies in Massachusetts is a remarkable achievement made possible by the hard work and dedication of our employees, and it is a further validation of our strategy of focusing on urgent unmet needs in the acute care environment. Last year was another year of strong performance for Cubist as reflected by today's recognition. The company grew both the top and bottom line, while bringing in additional acute care assets and progressing exciting and important pipeline programs from the company's own discovery activities. The Company also met or exceeded all of its financial guidance for the year." About The Boston Globe's annual Globe 100 rankings
The 21st annual Globe 100 ranks Massachusetts-based public companies based on financial data from the four quarters ending closest to December 31, 2008, and for corresponding quarters a year earlier. To be eligible, the company must be traded publicly for the entire 2008 calendar year on the New York Stock Exchange, the NASDAQ or the American Stock Exchange and report revenue and profit for both 2007 and 2008. Companies are ranked on four criteria: return on average equity, one-year percentage change in revenue, one-year percentage change in profit margin and 2008 revenue.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist began promoting MERREM® I.V. (meropenem for injection) in the United States. MERREM is an established broad spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials -- CONSERV™-1 and the planned CONSERV™-2 -- for the reduction of blood loss during cardiothoracic surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc. AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.
Contact: Cubist Pharmaceuticals, Inc. Eileen C. McIntyre, 781-860-8533 Senior Director, Corporate Communications eileen.mcintyre@cubist.com or Weber Shandwick Tara Murphy, 617-520-7045 tmurphy@webershandwick.com
Michael W. Bonney, Cubist's president and CEO, said: "Being #1 in the Globe 100 list of the best-performing public companies in Massachusetts is a remarkable achievement made possible by the hard work and dedication of our employees, and it is a further validation of our strategy of focusing on urgent unmet needs in the acute care environment. Last year was another year of strong performance for Cubist as reflected by today's recognition. The company grew both the top and bottom line, while bringing in additional acute care assets and progressing exciting and important pipeline programs from the company's own discovery activities. The Company also met or exceeded all of its financial guidance for the year." About The Boston Globe's annual Globe 100 rankings
The 21st annual Globe 100 ranks Massachusetts-based public companies based on financial data from the four quarters ending closest to December 31, 2008, and for corresponding quarters a year earlier. To be eligible, the company must be traded publicly for the entire 2008 calendar year on the New York Stock Exchange, the NASDAQ or the American Stock Exchange and report revenue and profit for both 2007 and 2008. Companies are ranked on four criteria: return on average equity, one-year percentage change in revenue, one-year percentage change in profit margin and 2008 revenue.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist began promoting MERREM® I.V. (meropenem for injection) in the United States. MERREM is an established broad spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials -- CONSERV™-1 and the planned CONSERV™-2 -- for the reduction of blood loss during cardiothoracic surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc. AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.
Contact: Cubist Pharmaceuticals, Inc. Eileen C. McIntyre, 781-860-8533 Senior Director, Corporate Communications eileen.mcintyre@cubist.com or Weber Shandwick Tara Murphy, 617-520-7045 tmurphy@webershandwick.com